Loading...
•
Sep 30, 2024
MannKind Q3 2024 Earnings Report
MannKind reported revenue growth driven by Tyvaso DPI and progress in clinical development programs.
Key Takeaways
MannKind Corporation reported a 37% increase in total revenues for Q3 2024 compared to Q3 2023, reaching $70 million. The growth was primarily driven by increased royalties from Tyvaso DPI and higher collaboration and services revenue. The company also made significant progress in its clinical development programs, including the Phase 3 trial of MNKD-101 and the successful completion of the Phase 1 trial of MNKD-201.
Total revenues for Q3 2024 reached $70 million, a 37% increase compared to Q3 2023.
Royalties for Tyvaso DPI increased by 34% due to increased sales by United Therapeutics.
Collaboration and services revenue increased by 78%, primarily due to increased manufacturing activities for Tyvaso DPI.
Afrezza net revenue increased by 12% due to higher demand and improved gross-to-net adjustments.
Revenue by Segment
Forward Guidance
MannKind anticipates several milestones in the near future, including data read-outs from clinical studies and regulatory submissions.
Positive Outlook
- Primary endpoint analysis results from the Afrezza INHALE-1 Pediatric Phase 3 clinical trial are expected in 4Q 2024.
- Six-month data with safety extension from the Afrezza INHALE-1 Pediatric Phase 3 clinical trial are expected in 1H 2025.
- Additional data from the Afrezza INHALE-3 Phase 4 clinical trial will be presented at ATTD and other conferences in 1H 2025.
- Trial for MNKD-101 is cleared to proceed in four countries, with a fifth expected in 4Q 2024.
- FDA End-of-Phase 1 meeting for MNKD-201 is expected in 1H 2025.
Challenges Ahead
- Risks associated with developing product candidates.
- Risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data.
- Risks associated with safety and other complications of our products and product candidates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...